

E.1 Immunomodulatory drugs (rituximab, rintatolimod, IV immunoglobulin G) versus placebo

Figure 2: Quality of Life: SF36 (max % change from baseline) at 10 months (rituximab)




Figure 3: Fatigue/fatigability: Fatigue severity scale at 18 months (rituximab)




Figure 4: Fatigue/fatigability: Fatigue numeric rating scale 0-10 at 16-20 months (rituximab)




Figure 5: Psychological status: Hamilton Depression Scale at 6 months (IVIG)




Figure 6: Psychological status: Zung Self-Rating Depression Scale at 6 months (IVIG)




Figure 7: Psychological status: mental health on the Medical Outcome Study Short Form at 150 days (IVIG)




Figure 8: Physical functioning: physical functioning on the Medical Outcome Study Short Form at 150 days (IVIg)




Figure 9: Physical functioning: physical functioning on the SF36 at 24 months (rituximab)




Figure 10: Physical functioning: functional level % at 16-20 months (rituximab)




Figure 11: SAEs with possible/probable relation to intervention (rintatolimod)




Figure 12: Adverse events: major adverse events (IVIG)




Figure 13: Adverse events: constitutional symptoms (IVIG)




Figure 14: Adverse events: any SAEs with possible/probable relation to intervention (rituximab)




Figure 15: Adverse events: any AEs of at least moderate severity with possible/probable relation to intervention (rituximab)




Figure 16: Adverse events: suspected unexpected adverse reactions (rituximab)




Figure 17: Activity levels: mean steps/24 hrs (rituximab)




Figure 18: Exercise performance measure: Treadmill exercise duration in seconds at 42 weeks (rintatolimod)




Figure 19: Return to school or work: Resumption of pre-morbid employment status (full-time) at 6 months (IVIG)




Figure 20: Symptom scales: Marked reduction in symptoms and improvement in functional capacity (IVIG)

